ID   RED1_RAT                Reviewed;         711 AA.
AC   P51400;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   02-OCT-2024, entry version 146.
DE   RecName: Full=Double-stranded RNA-specific editase 1;
DE            EC=3.5.4.37;
DE   AltName: Full=RNA-editing deaminase 1;
DE   AltName: Full=RNA-editing enzyme 1;
DE   AltName: Full=dsRNA adenosine deaminase;
GN   Name=Adarb1; Synonyms=Red1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8559253; DOI=10.1038/379460a0;
RA   Melcher T., Maas S., Herb A., Sprengel R., Seeburg P.H., Higuchi M.;
RT   "A mammalian RNA editing enzyme.";
RL   Nature 379:460-464(1996).
RN   [2]
RP   FUNCTION.
RX   PubMed=20501795; DOI=10.1096/fj.09-152363;
RA   Yang L., Zhao L., Gan Z., He Z., Xu J., Gao X., Wang X., Han W., Chen L.,
RA   Xu T., Li W., Liu Y.;
RT   "Deficiency in RNA editing enzyme ADAR2 impairs regulated exocytosis.";
RL   FASEB J. 24:3720-3732(2010).
RN   [3]
RP   STRUCTURE BY NMR OF 74-301, FUNCTION, MUTAGENESIS OF LYS-128 AND LYS-281,
RP   AND RNA-BINDING.
RX   PubMed=16472753; DOI=10.1016/j.str.2005.11.013;
RA   Stefl R., Xu M., Skrisovska L., Emeson R.B., Allain F.H.;
RT   "Structure and specific RNA binding of ADAR2 double-stranded RNA binding
RT   motifs.";
RL   Structure 14:345-355(2006).
RN   [4]
RP   STRUCTURE BY NMR OF 74-301 IN COMPLEX WITH RNA, FUNCTION, AND MUTAGENESIS
RP   OF MET-84; 104-VAL-HIS-105; MET-238 AND 258-SER-HIS-259.
RX   PubMed=20946981; DOI=10.1016/j.cell.2010.09.026;
RA   Stefl R., Oberstrass F.C., Hood J.L., Jourdan M., Zimmermann M.,
RA   Skrisovska L., Maris C., Peng L., Hofr C., Emeson R.B., Allain F.H.;
RT   "The solution structure of the ADAR2 dsRBM-RNA complex reveals a sequence-
RT   specific readout of the minor groove.";
RL   Cell 143:225-237(2010).
CC   -!- FUNCTION: Catalyzes the hydrolytic deamination of adenosine to inosine
CC       in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This
CC       may affect gene expression and function in a number of ways that
CC       include mRNA translation by changing codons and hence the amino acid
CC       sequence of proteins; pre-mRNA splicing by altering splice site
CC       recognition sequences; RNA stability by changing sequences involved in
CC       nuclease recognition; genetic stability in the case of RNA virus
CC       genomes by changing sequences during viral RNA replication; and RNA
CC       structure-dependent activities such as microRNA production or targeting
CC       or protein-RNA interactions. Can edit both viral and cellular RNAs and
CC       can edit RNAs at multiple sites (hyper-editing) or at specific sites
CC       (site-specific editing). Its cellular RNA substrates include: bladder
CC       cancer-associated protein (BLCAP), neurotransmitter receptors for
CC       glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor
CC       (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA
CC       editing of transcripts encoding these proteins results in amino acid
CC       substitutions which consequently alter their functional activities.
CC       Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the
CC       adenosine in hotspot1 much less efficiently (By similarity). Can
CC       inhibit cell proliferation and migration and can stimulate exocytosis.
CC       {ECO:0000250, ECO:0000269|PubMed:16472753, ECO:0000269|PubMed:20501795,
CC       ECO:0000269|PubMed:20946981}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=adenosine in double-stranded RNA + H(+) + H2O = inosine in
CC         double-stranded RNA + NH4(+); Xref=Rhea:RHEA:10120, Rhea:RHEA-
CC         COMP:13885, Rhea:RHEA-COMP:13886, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:28938, ChEBI:CHEBI:74411,
CC         ChEBI:CHEBI:82852; EC=3.5.4.37;
CC   -!- COFACTOR:
CC       Name=1D-myo-inositol hexakisphosphate; Xref=ChEBI:CHEBI:58130;
CC         Evidence={ECO:0000250};
CC       Note=Binds 1 myo-inositol hexakisphosphate (IP6) per subunit.
CC       {ECO:0000250};
CC   -!- SUBUNIT: Homodimer. Homodimerization is essential for its catalytic
CC       activity (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Nucleus, nucleolus
CC       {ECO:0000250}. Note=Shuttles between nucleoli and the nucleoplasm.
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Brain and peripheral tissues.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U43534; AAA96755.1; -; mRNA.
DR   PIR; S68443; S68443.
DR   RefSeq; NP_001104525.1; NM_001111055.1.
DR   RefSeq; NP_001104526.1; NM_001111056.1.
DR   RefSeq; NP_001104527.1; NM_001111057.1.
DR   RefSeq; NP_037026.2; NM_012894.2.
DR   PDB; 2B7T; NMR; -; A=74-146.
DR   PDB; 2B7V; NMR; -; A=231-301.
DR   PDB; 2L3C; NMR; -; A=74-147.
DR   PDB; 2L3J; NMR; -; A=74-301.
DR   PDBsum; 2B7T; -.
DR   PDBsum; 2B7V; -.
DR   PDBsum; 2L3C; -.
DR   PDBsum; 2L3J; -.
DR   AlphaFoldDB; P51400; -.
DR   BMRB; P51400; -.
DR   SMR; P51400; -.
DR   STRING; 10116.ENSRNOP00000069261; -.
DR   PhosphoSitePlus; P51400; -.
DR   PaxDb; 10116-ENSRNOP00000001642; -.
DR   GeneID; 25367; -.
DR   KEGG; rno:25367; -.
DR   UCSC; RGD:2033; rat.
DR   AGR; RGD:2033; -.
DR   CTD; 104; -.
DR   RGD; 2033; Adarb1.
DR   eggNOG; KOG2777; Eukaryota.
DR   InParanoid; P51400; -.
DR   OrthoDB; 118472at2759; -.
DR   PhylomeDB; P51400; -.
DR   Reactome; R-RNO-75102; C6 deamination of adenosine.
DR   Reactome; R-RNO-77042; Formation of editosomes by ADAR proteins.
DR   EvolutionaryTrace; P51400; -.
DR   PRO; PR:P51400; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005730; C:nucleolus; ISO:RGD.
DR   GO; GO:0005654; C:nucleoplasm; IDA:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0045202; C:synapse; ISO:RGD.
DR   GO; GO:0003726; F:double-stranded RNA adenosine deaminase activity; IDA:RGD.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:RGD.
DR   GO; GO:0042802; F:identical protein binding; IPI:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IDA:RGD.
DR   GO; GO:0008251; F:tRNA-specific adenosine deaminase activity; IBA:GO_Central.
DR   GO; GO:0006382; P:adenosine to inosine editing; IDA:RGD.
DR   GO; GO:0016553; P:base conversion or substitution editing; IDA:RGD.
DR   GO; GO:0021610; P:facial nerve morphogenesis; ISO:RGD.
DR   GO; GO:0021618; P:hypoglossal nerve morphogenesis; ISO:RGD.
DR   GO; GO:0060384; P:innervation; ISO:RGD.
DR   GO; GO:0061744; P:motor behavior; ISO:RGD.
DR   GO; GO:0097049; P:motor neuron apoptotic process; ISO:RGD.
DR   GO; GO:0016556; P:mRNA modification; IDA:RGD.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0035264; P:multicellular organism growth; ISO:RGD.
DR   GO; GO:0060415; P:muscle tissue morphogenesis; ISO:RGD.
DR   GO; GO:0030336; P:negative regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; ISS:UniProtKB.
DR   GO; GO:0044387; P:negative regulation of protein kinase activity by regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0050884; P:neuromuscular process controlling posture; ISO:RGD.
DR   GO; GO:0007274; P:neuromuscular synaptic transmission; ISO:RGD.
DR   GO; GO:0050685; P:positive regulation of mRNA processing; IDA:RGD.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; ISS:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; ISS:UniProtKB.
DR   GO; GO:0006396; P:RNA processing; ISS:HGNC-UCL.
DR   GO; GO:0021965; P:spinal cord ventral commissure morphogenesis; ISO:RGD.
DR   CDD; cd19895; DSRM_RED1_rpt1; 1.
DR   CDD; cd19898; DSRM_RED1_rpt2; 1.
DR   DisProt; DP03065; -.
DR   Gene3D; 3.30.160.20; -; 2.
DR   InterPro; IPR002466; A_deamin.
DR   InterPro; IPR044458; ADAR2_DSRM_1.
DR   InterPro; IPR044459; ADAR2_DSRM_2.
DR   InterPro; IPR014720; dsRBD_dom.
DR   PANTHER; PTHR10910:SF58; DOUBLE-STRANDED RNA-SPECIFIC EDITASE 1; 1.
DR   PANTHER; PTHR10910; EUKARYOTE SPECIFIC DSRNA BINDING PROTEIN; 1.
DR   Pfam; PF02137; A_deamin; 1.
DR   Pfam; PF00035; dsrm; 2.
DR   SMART; SM00552; ADEAMc; 1.
DR   SMART; SM00358; DSRM; 2.
DR   SUPFAM; SSF54768; dsRNA-binding domain-like; 2.
DR   PROSITE; PS50141; A_DEAMIN_EDITASE; 1.
DR   PROSITE; PS50137; DS_RBD; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Hydrolase; Metal-binding; mRNA processing; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; RNA-binding; Zinc.
FT   CHAIN           1..711
FT                   /note="Double-stranded RNA-specific editase 1"
FT                   /id="PRO_0000171781"
FT   DOMAIN          78..144
FT                   /note="DRBM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00266"
FT   DOMAIN          231..298
FT                   /note="DRBM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00266"
FT   DOMAIN          370..707
FT                   /note="A to I editase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00240"
FT   REGION          1..79
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          83..88
FT                   /note="Interaction with substrate RNA"
FT   REGION          104..105
FT                   /note="Interaction with substrate RNA"
FT   REGION          176..220
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          237..242
FT                   /note="Interaction with substrate RNA"
FT   REGION          259
FT                   /note="Interaction with substrate RNA"
FT   COMPBIAS        195..215
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        396
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00240"
FT   BINDING         394
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00240"
FT   BINDING         400
FT                   /ligand="1D-myo-inositol hexakisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58130"
FT                   /evidence="ECO:0000250"
FT   BINDING         401
FT                   /ligand="1D-myo-inositol hexakisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58130"
FT                   /evidence="ECO:0000250"
FT   BINDING         451
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00240"
FT   BINDING         526
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00240"
FT   BINDING         529
FT                   /ligand="1D-myo-inositol hexakisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58130"
FT                   /evidence="ECO:0000250"
FT   BINDING         532
FT                   /ligand="1D-myo-inositol hexakisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58130"
FT                   /evidence="ECO:0000250"
FT   BINDING         639
FT                   /ligand="1D-myo-inositol hexakisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58130"
FT                   /evidence="ECO:0000250"
FT   BINDING         672
FT                   /ligand="1D-myo-inositol hexakisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58130"
FT                   /evidence="ECO:0000250"
FT   BINDING         682
FT                   /ligand="1D-myo-inositol hexakisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58130"
FT                   /evidence="ECO:0000250"
FT   BINDING         700
FT                   /ligand="1D-myo-inositol hexakisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58130"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         149
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P78563"
FT   MUTAGEN         84
FT                   /note="M->A: Strongly reduced RNA editing activity."
FT                   /evidence="ECO:0000269|PubMed:20946981"
FT   MUTAGEN         104..105
FT                   /note="VH->AA: Strongly reduced RNA editing activity."
FT                   /evidence="ECO:0000269|PubMed:20946981"
FT   MUTAGEN         128
FT                   /note="K->A: Reduced RNA editing activity; when associated
FT                   with A-281."
FT                   /evidence="ECO:0000269|PubMed:16472753"
FT   MUTAGEN         238
FT                   /note="M->A: Strongly reduced RNA editing activity."
FT                   /evidence="ECO:0000269|PubMed:20946981"
FT   MUTAGEN         258..259
FT                   /note="SH->AA: Abolishes RNA editing activity."
FT                   /evidence="ECO:0000269|PubMed:20946981"
FT   MUTAGEN         281
FT                   /note="K->A: Reduced RNA editing activity; when associated
FT                   with A-128."
FT                   /evidence="ECO:0000269|PubMed:16472753"
FT   STRAND          76..79
FT                   /evidence="ECO:0007829|PDB:2B7T"
FT   HELIX           80..89
FT                   /evidence="ECO:0007829|PDB:2B7T"
FT   STRAND          94..101
FT                   /evidence="ECO:0007829|PDB:2B7T"
FT   STRAND          103..106
FT                   /evidence="ECO:0007829|PDB:2B7T"
FT   STRAND          108..126
FT                   /evidence="ECO:0007829|PDB:2B7T"
FT   HELIX           127..143
FT                   /evidence="ECO:0007829|PDB:2B7T"
FT   STRAND          183..186
FT                   /evidence="ECO:0007829|PDB:2L3J"
FT   STRAND          193..195
FT                   /evidence="ECO:0007829|PDB:2L3J"
FT   STRAND          197..201
FT                   /evidence="ECO:0007829|PDB:2L3J"
FT   STRAND          217..219
FT                   /evidence="ECO:0007829|PDB:2L3J"
FT   STRAND          221..224
FT                   /evidence="ECO:0007829|PDB:2L3J"
FT   HELIX           236..243
FT                   /evidence="ECO:0007829|PDB:2B7V"
FT   STRAND          248..253
FT                   /evidence="ECO:0007829|PDB:2B7V"
FT   TURN            258..260
FT                   /evidence="ECO:0007829|PDB:2B7V"
FT   STRAND          263..268
FT                   /evidence="ECO:0007829|PDB:2B7V"
FT   STRAND          273..280
FT                   /evidence="ECO:0007829|PDB:2B7V"
FT   HELIX           281..299
FT                   /evidence="ECO:0007829|PDB:2B7V"
SQ   SEQUENCE   711 AA;  77925 MW;  5A25C4B202530C54 CRC64;
     MDIEDEENMS SSSIDVKENR NLDNMPPKDS STPGPGEGIP LSNGGGGSTS RKRPLEEGSN
     GHSKYRLKKR RKTPGPVLPK NALMQLNEIK PGLQYMLLSQ TGPVHAPLFV MSVEVNGQVF
     EGSGPTKKKA KLHAAEKALR SFVQFPNASE AHLAMGRTLS VNTDFTSDQA DFPDTLFNGF
     ETPDKSEPPF YVGSNGDDSF SSSGDVSLSA SPVPASLTQP PLPIPPPFPP PSGKNPVMIL
     NELRPGLKYD FLSESGESHA KSFVMSVVVD GQFFEGSGRN KKLAKARAAQ SALATVFNLH
     LDQTPSRQPV LSEGLQLHLP QVLADAVSRL VLGKFSDLTD NFSSPHARRK VLSGVVMTTG
     TDVKDAKVIS VSTGTKCING EYMSDRGLAL NDCHAEIISR RSLLRFLYAQ LELYLNNKED
     QKKSIFQKSE RGGFRLKDTV QFHLYISTSP CGDARIFSPH EPVLEGMAPD SHQLTEPADR
     HPNRKARGQL RTKIESGEGT IPVRSNASIQ TWDGVLQGER LLTMSCSDKI ARWNVVGIQG
     ALLSIFVEPI YFSSIILGSL YHGDHLSRAM YQRISNIEDL PPLYTLNKPL LSGISNAEAR
     QPGKAPNFSV NWTVGDTAIE VINATTGKDE LGRPSRLCKH ALYCRWMRVH GKVPPHLLRT
     KITKPTTYHE SKLAAKEYQA AKARLFTAFI KAGLGAWVEK PTEQDQFSFT P
//
